Electrophysiology of Ethmozine (moricizine HCl) for ventricular tachycardia.
Moricizine HCl, an antiarrhythmic phenothiazine drug, was investigated for its efficacy against ventricular tachycardia (VT) in a group of 60 patients from 8 institutions using electrophysiologic testing before and after oral administration. Moricizine HCl significantly prolonged PR, QRS, AH and HV intervals and cycle length for atrioventricular nodal block, but had minimal or no effect on repolarization or cardiac refractory periods. Induction of sustained VT (in 33 patients) and nonsustained VT (in 14 patients) occurred at baseline. During moricizine HCl therapy, sustained VT was induced in 31 patients and nonsustained VT in 7 patients. In individual patients, suppression of VT induction was obtained in 18% of patients with sustained VT and in 27% of patients with nonsustained VT. Cycle length of induced VT was significantly prolonged by moricizine HCl therapy. During prospective follow-up of 37 patients, electrophysiologic study predicted recurrence of nonrecurrence of VT with a sensitivity value of 82% and specificity of 65%.
Wyndham
C R
CR
Department of Medicine, Baylor College of Medicine, Houston, Texas.
Pratt
C M
CM
Mann
D E
DE
Winkle
R A
RA
Somberg
J
J
de Maria
A N
AN
Josephson
M E
ME
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002304:Cardiac Pacing, Artificial; D004558:Electric Stimulation; D004594:Electrophysiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016293:Moricizine; D010640:Phenothiazines / Q000627:therapeutic use*; D012008:Recurrence; D012032:Refractory Period, Electrophysiological; D013610:Tachycardia / Q000188:drug therapy / Q000503:physiopathology*; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000503:physiopathology*
D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D016293:Moricizine